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1. INTRODUCTION {#cam42679-sec-0005}
===============

Gallbladder cancer (GBC) is a common malignant tumor in the biliary system, accounting for approximately 2/3 of biliary system tumors, and its incidence is increasing.[1](#cam42679-bib-0001){ref-type="ref"}, [2](#cam42679-bib-0002){ref-type="ref"} Although relatively uncommon, it is the sixth common form of digestive system cancer. In 2019, an estimated 12 360 new cases were diagnosed, and 3960 patients died from GBC and other biliary cancer in the United States.[3](#cam42679-bib-0003){ref-type="ref"} Because of the insidious onset, rapid progression, and early asymptomatic characteristics of GBC, diagnosis is usually not made until intraoperative and postoperative pathological examinations, when the disease is already in moderate and advanced stages, and the therapeutic effect are poor.[4](#cam42679-bib-0004){ref-type="ref"}

The median survival time of patients with GBC is less than 1 year, the overall survival (OS) is approximately 17.8%‐21.7%, and the 5‐year OS is only 5%.[1](#cam42679-bib-0001){ref-type="ref"}, [5](#cam42679-bib-0005){ref-type="ref"} GBC treatments include surgery, chemotherapy (CT), radiotherapy (RT), and other immunotherapy.[6](#cam42679-bib-0006){ref-type="ref"}, [7](#cam42679-bib-0007){ref-type="ref"}, [8](#cam42679-bib-0008){ref-type="ref"} Although GBC has high invasiveness and metastasis, surgical resection remains recognized as the best treatment.[9](#cam42679-bib-0009){ref-type="ref"}, [10](#cam42679-bib-0010){ref-type="ref"} The 5‐year survival rate of early T1 GBC patients is as high as 95%‐100%. However, for patients with T3 stage and T4 stage, the 5‐year survival rate is only 23% and 12%, respectively.[11](#cam42679-bib-0011){ref-type="ref"}

Both in China and abroad, most diagnosed GBC patients are in moderate and advanced stages. The treatment of GBC still confuses many physicians, even experienced surgeons. The treatment of patients with advanced GBC remains especially controversial. In our study, we used data from the surveillance, epidemiology, and end results (SEER) cancer registration database to explore the treatment options for patients with advanced GBC.

2. PATIENTS AND METHODS {#cam42679-sec-0006}
=======================

2.1. Patients selection {#cam42679-sec-0007}
-----------------------

The SEER database is currently the largest publicly available cancer database, covering approximately 28% of the US population.[12](#cam42679-bib-0012){ref-type="ref"} All cases are from the SEER Program (<http://www.seer.cancer.gov>) SEER\*Stat database released in November 2017: version 8.3.5; SEER 18 Regs Custom Data (with additional treatment field), Nov 2017 Sub (1973‐2015 varying) database. The SEER database contains information about patient demographics and cancer characteristics, such as sex, age at diagnosis, year of diagnosis, race, marital status, tumor grade and stage, histological type, treatment, and patient survival time.

Using the \"Primary Site---labeled\" variable, we selected tumor cases from the primary site of the gallbladder diagnosed between 2004 and 2015. The study included only patients with American Joint Committee on Cancer (AJCC) stage III and IV cancer. According to the 2004 AJCC staging principle, stage III is defined as "T4M0, any N," and stage IV is defined as "M1, any T or any N." Only patients above 18 years of age were included in this study. Patients with any of the following criteria were also excluded: unknown treatment, not the first tumor, unknown survival time, and unknown marital status. Finally, 4527 eligible patients diagnosed with GBC remained.

2.2. Study variables {#cam42679-sec-0008}
--------------------

Definition and information about the variables of sex, diagnosis age, year of diagnosis, race, marital status, tumor grade, histological type, and survival time can be found in the SEER database. OS and cancer‐specific survival (CSS) were the primary study endpoints. For OS, death from any cause was considered as an event, and the survivor was regarded as censored. For the CSS analysis, deaths caused by GBC were considered events, and deaths from other causes or survivors were censored.

For the diagnosis age, we divided all patients into three groups: less than 60 years old, 60‐80 years old, and older than 80 years old.

For marital status, patients were divided into a Married group, an Unmarried group, and an Unknown marital status group. Unmarried patients include Single, Separated, Divorced, and Widowed.

For race, patients were divided into a Non‐Hispanic White group, a Non‐Hispanic Black group, a Hispanic group, and an Others group.

The ICD‐0‐3 site/histology validation list was used to distinguish adenocarcinoma, squamous cell carcinoma, and other histological types.

Grade was defined by the following codes: well differentiated (Grade I); moderately differentiated (Grade II); poorly differentiated (Grade III); undifferentiated (Grade IV); and unknown grade.

2.3. Statistical analysis {#cam42679-sec-0009}
-------------------------

Pearson\'s chi‐square analysis was used to analyze and evaluate the different clinical characteristics between different treatment patterns. The Kaplan‐Meier curve was used to estimate the OS and CSS in different groups, and the differences between the curves were analyzed by log‐rank test. Univariate and multivariate Cox regression models were performed to estimate the hazard ratios (HR) and 95% confidence interval (CI) to analyze the independent prognostic factors associated with OS and CSS in GBC patients.

According to AJCC stage, the patients were divided into AJCC stage III and IV groups. 1:1 propensity score matching (PSM) was to reduce the selection bia of the two groups of baseline variables, including age, race, marital status, histological type, grade, and treatment pattern seven variables. After PSM, the clinicopathological features of the patients were reevaluated according to AJCC stage. All statistical analyses were conducted with the Statistical Package for the Social Sciences software (version 24.0; IBM Corporation). A *P* value ≤ .05 was considered statistically significant.

3. RESULTS {#cam42679-sec-0010}
==========

3.1. Demographic and clinical characteristics {#cam42679-sec-0011}
---------------------------------------------

From 2004 to 2015, our study cohort included a total of 4527 eligible GBC patients. Among them, 1575 patients with "No surgery/No CT," 938 patients with "Surgery", 1222 patients with "CT" and 792 patients with "Surgery + CT". The demographic and clinical characteristics of GBC patients with different treatment patterns are shown in Table [1](#cam42679-tbl-0001){ref-type="table"}. Male patients accounted for 30.7%, and female patients accounted for 69.3%. Moreover, there were 288 patients with AJCC stage III and 4239 with AJCC stage IV. Chi‐square test showed significant differences in some variables and treatment patterns, including diagnosis age, sex, race, marital status, histological type, tumor grade, and AJCC stage (All *P* \< .05).

###### 

Characteristics for different metastasis in our study

  Characteristic            Total   No surgery/No CT   Surgery      CT            Surgery + CT   *P* value
  ------------------------- ------- ------------------ ------------ ------------- -------------- -----------
  Sex                                                                                            
  Female                    1391    509 (32.3)         272 (29.0)   403 (33.0)    207 (26.1)     .003
  Male                      3136    1066 (67.7)        666 (71.0)   819 (67.0)    585 (73.9)     
  Age at diagnosis                                                                               
  \<60 y                    1057    210 (13.3)         164 (17.5)   405 (33.1)    278 (35.1)     \<.001
  60‐80 y                   2551    825 (52.4)         540 (57.6)   718 (58.8)    468 (59.1)     
  \>80 y                    919     540 (34.3)         234 (24.9)   99 (8.1)      46 (5.8)       
  Race                                                                                           
  Non‐Hispanic White        2543    873 (55.4)         530 (56.5)   689 (56.4)    451 (56.9)     .007
  Non‐Hispanic Black        580     190 (12.1)         99 (10.6)    189 (15.5)    102 (12.9)     
  Hispanic                  922     329 (20.9)         216 (23.0)   214 (17.5)    163 (20.6)     
  Others                    482     183 (11.6)         93 (9.9)     130 (10.6)    76 (9.6)       
  Marital status                                                                                 
  Married                   2352    651 (41.3)         473 (50.4)   741 (60.6)    487 (61.8)     \<.001
  Divorced/separated        483     159 (10.1)         88 (9.4)     145 (11.9)    91 (11.5)      
  Windowed                  1066    516 (32.8)         259 (27.6)   185 (15.1)    106 (13.4)     
  Single                    626     249 (15.8)         118 (12.6)   151 (12.4)    108 (13.6)     
  Histological type                                                                              
  Adenocarcinoma            3278    923 (58.6)         773 (82.4)   914 (74.8)    668 (84.3)     \<.001
  Squamous cell carcinoma   167     44 (2.8)           54 (5.8)     31 (2.5)      38 (4.8)       
  Others                    1082    608 (38.6)         111 (11.8)   277 (22.7)    86 (10.9)      
  Grade                                                                                          
  Grade I                   157     20 (1.3)           62 (6.6)     23 (1.9)      52 (6.6)       \<.001
  Grade II                  804     105 (6.7)          281 (30.0)   121 (9.9)     297 (37.5)     
  Grade III                 1219    221 (14.0)         477 (50.9)   184 (15.1)    337 (42.6)     
  Grade IV                  86      15 (1.0)           35 (3.7)     12 (1.0)      24 (3.0)       
  Unknown                   2261    1214 (77.1)        83 (8.8)     882 (72.2)    82 (10.4)      
  AJCC stage                                                                                     
  III                       288     84 (5.3)           72 (7.7)     56 (4.6)      76 (9.6)       \<.001
  IV                        4239    1491 (94.7)        866 (92.3)   1166 (95.4)   716 (90.4)     

Percentages may not total 100 because of rounding.

Abbreviations: AJCC, American Joint Committee on Cancer; CT, chemotherapy; Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated.
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3.2. Trend in different treatment patterns {#cam42679-sec-0012}
------------------------------------------

As shown in Table [2](#cam42679-tbl-0002){ref-type="table"}, the proportion of patients who accepted the \"No surgery/No CT\" or \"Surgery + CT\" models remained relatively stable between 2004 and 2015. Simultaneously, the number and proportion of patients receiving the \"CT\" model increased each year. The proportion of the \"Surgery\" treatment was significantly lower in patients with advanced GBC compared with the increase in \"CT\" mode (Figure [1](#cam42679-fig-0001){ref-type="fig"}).

###### 

Changes in the number and proportion of the four treatment methods between 2004 and 2015

  Characteristic      Total   No surgery/No CT   Surgery      CT           Surgery + CT   *P* value
  ------------------- ------- ------------------ ------------ ------------ -------------- -----------
  Year of diagnosis                                                                       
  2004                315     104 (33.0)         87 (27.6)    64 (20.3)    60 (19.0)      \<.001
  2005                347     123 (35.4)         104 (30.0)   61 (17.6)    59 (17.0)      
  2006                322     120 (37.3)         79 (8.4)     64 (19.9)    59 (18.3)      
  2007                332     126 (38.0)         81 (24.4)    79 (23.8)    46 (13.9)      
  2008                311     112 (36.0)         76 (24.4)    64 (20.6)    59 (19.0)      
  2009                374     119 (31.8)         83 (22.2)    92 (24.6)    80 (21.4)      
  2010                396     149 (37.6)         78 (19.7)    114 (28.8)   55 (13.9)      
  2011                398     131 (32.9)         71 (17.8)    111 (27.9)   85 (21.4)      
  2012                427     142 (33.3)         83 (19.4)    132 (30.9)   70 (16.4)      
  2013                439     154 (35.1)         62 (14.1)    153 (34.9)   70 (15.9)      
  2014                421     139 (33.0)         72 (17.1)    139 (33.0)   71 (16.9)      
  2015                445     156 (35.1)         62 (13.9)    149 (33.5)   78 (17.5)      

Percentages may not total 100 because of rounding.

Abbreviation: CT, chemotherapy.
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![Trends in the proportion of four treatment modes in patients with advanced gallbladder cancer between 2004 and 2015](CAM4-9-141-g001){#cam42679-fig-0001}

3.3. Identification of prognostic factors of OS and CSS in patients with advanced GBC {#cam42679-sec-0013}
-------------------------------------------------------------------------------------

Univariate and multivariate Cox regression were used to analyze the factors associated with OS and CSS in patients with advanced GBC. Before matching, as shown in Table [3](#cam42679-tbl-0003){ref-type="table"}, the age at diagnosis, histological type, tumor grade, AJCC stage, and treatment pattern affected the OS and CSS in patients with advanced GBC. Multivariate Cox regression showed that "surgery" (vs "No surgery/No CT"; HR = 0.60, 95% CI 0.55‐0.66, *P* \< .001), "CT" (vs "No surgery/No CT"; HR = 0.44, 95% CI 0.40‐0.48, *P* \< .001), and "Surgery + CT" (vs "No surgery/No CT"; HR = 0.29, 95% CI 0.26‐0.33, *P* \< .001) were associated with OS (Figure [2](#cam42679-fig-0002){ref-type="fig"}A). Similarly, in terms of CSS, multivariate Cox regression analysis also indicated that treatment pattern was a prognostic factor for patients with advanced GBC ("surgery" vs "No surgery/No CT"; HR = 0.65, 95% CI 0.57‐0.74, *P* \< .001; "CT" vs "No surgery/No CT"; HR = 0.44, 95% CI 0.39‐0.50, *P* \< .001; "Surgery + CT" vs "No surgery/No CT"; HR = 0.33, 95% CI 0.29‐0.39, *P* \< .001) (Figure [2](#cam42679-fig-0002){ref-type="fig"}B).

###### 

Univariate and multivariate analysis of OS and CSS rates before propensity score matching

  Characteristic            OS                 CSS                                                                                 
  ------------------------- ------------------ -------- ------------------ -------- ------------------ -------- ------------------ --------
  Sex                                                                                                                              
  Female                    Reference                   Reference                   Reference                                       
  Male                      0.94 (0.88‐1.00)   .049     ---                .243     1.02 (0.94‐1.12)   .624                         
  Age at diagnosis                                                                                                                 
  \<60 y                    Reference                   Reference                   Reference                   Reference           
  60‐80 y                   1.28 (1.19‐1.38)   \<.001   1.21 (1.12‐1.30)   \<.001   1.27 (1.14‐1.40)   \<.001   1.18 (1.06‐1.31)   .003
  \>80 y                    2.15 (1.96‐2.36)   \<.001   1.55 (1.41‐1.71)   \<.001   2.22 (1.96‐2.52)   \<.001   1.58 (1.37‐1.81)   \<.001
  Race                                                                                                                             
  Non‐Hispanic White        Reference                                               Reference                                       
  Non‐Hispanic Black        0.96 (0.87‐1.05)   .349                                 0.98 (0.86‐1.11)   .740                         
  Hispanic                  0.95 (0.88‐1.03)   .251                                 0.98 (0.88‐1.09)   .712                         
  Others                    0.96 (0.86‐1.06)   .372                                 1.06 (0.93‐1.21)   .366                         
  Marital status                                                                                                                   
  Married                   Reference                   Reference                   Reference                   Reference           
  Divorced/separated        1.11 (1.00‐1.23)   .046     ---                .204     1.17 (1.02‐1.34)   .022     1.16 (1.01‐1.33)   .033
  Windowed                  1.44 (1.33‐1.55)   \<.001   ---                .397     1.57 (1.42‐1.74)   \<.001   1.17 (1.05‐1.31)   .005
  Single                    1.17 (1.07‐1.28)   .001     ---                .255     1.23 (1.08‐1.39)   .001     1.14 (1.01‐1.30)   .039
  Histological type                                                                                                                
  Adenocarcinoma            Reference                   Reference                   Reference                   Reference           
  Squamous cell carcinoma   1.21 (1.03‐1.42)   .019     1.25 (1.06‐1.47)   .007     1.35 (1.11‐1.66)   .003     1.39 (1.13‐1.70)   .002
  Others                    1.31 (1.22‐1.40)   \<.001   1.01 (0.94‐1.09)   .721     1.04 (0.94‐1.15)   .459     0.83 (0.74‐0.92)   .001
  Grade                                                                                                                            
  Grade I                   Reference                   Reference                   Reference                   Reference           
  Grade II                  1.13 (0.04‐1.35)   .204     1.24 (1.03‐1.49)   .022     1.10 (0.87‐1.39)   .446     1.21 (0.96‐1.54)   .105
  Grade III                 1.64 (1.37‐1.96)   \<.001   1.68 (1.41‐2.01)   \<.001   1.56 (1.24‐1.96)   \<.001   1.66 (1.32‐2.08)   \<.001
  Grade IV                  1.44 (1.09‐1.91)   .010     1.54 (1.16‐2.04)   .003     1.49 (1.05‐2.13)   .027     1.77 (1.24‐2.54)   .002
  Unknown                   1.85 (1.56‐2.20)   \<.001   1.46 (1.22‐1.75)   \<.001   1.56 (1.25‐1.95)   \<.001   1.38 (1.09‐1.74)   .008
  AJCC stage                                                                                                                       
  III                       Reference                   Reference                   Reference                   Reference           
  IV                        1.40 (1.23‐1.59)   \<.001   1.38 (1.21‐1.57)   \<.001   1.45 (1.21‐1.72)   \<.001   1.44 (1.21‐1.72)   \<.001
  Treatment pattern                                                                                                                
  No surgery/No CT          Reference                   Reference                   Reference                   Reference           
  Surgery                   0.58 (0.53‐0.63)   \<.001   0.60 (0.55‐0.66)   \<.001   0.67 (0.60‐0.75)   \<.001   0.65 (0.57‐0.74)   \<.001
  CT                        0.41 (0.38‐0.44)   \<.001   0.44 (0.40‐0.48)   \<.001   0.41 (0.37‐0.46)   \<.001   0.44 (0.39‐0.50)   \<.001
  Surgery + CT              0.26 (0.24‐0.29)   \<.001   0.29 (0.26‐0.33)   \<.001   0.32 (0.28‐0.36)   \<.001   0.33 (0.29‐0.39)   \<.001

Abbreviations: AJCC, American Joint Committee on Cancer; CSS, cancer‐specific survival; CT, chemotherapy; Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; OS, overall survival.

Model was adjusted by sex, age, marital status, histological type, grade, AJCC stage, and treatment pattern.

Model was adjusted by age, marital status, histological type, grade, AJCC stage, and treatment pattern.

John Wiley & Sons, Ltd

![Overall survival and cancer‐specific survival curves of advanced gallbladder cancer patients. A, Overall survival; B, Cancer‐specific survival](CAM4-9-141-g002){#cam42679-fig-0002}

To better characterize the influence of treatment pattern on OS and CSS in patients with advanced GBC, we performed AJCC stage stratification on all patient parameters on the basis of multivariate analysis. We found that the treatment pattern was also an independent risk factor for patients with AJCC stage III and AJCC stage IV (Table [4](#cam42679-tbl-0004){ref-type="table"}). "Surgery," "CT," and "Surgery + CT" improve the AJCC stage III and AJCC stage IV patient OS and CSS. In particular, "Surgery + CT" could significantly improve OS and CSS in both AJCC stage III (HR = 0.36, 95% CI 0.22‐0.60, *P* \< .001) and AJCC stage IV (HR = 0.33, 95% CI 0.29‐0.39, *P* \< .001) groups (Figure [3](#cam42679-fig-0003){ref-type="fig"}).

###### 

Multivariate analysis of OS and CSS rates in AJCC stage III and stage IV before propensity score matching

  Characteristic            AJCC stage III (n = 288)   AJCC stage IV (n = 4239)                                                                              
  ------------------------- -------------------------- -------------------------- ------------------ -------- ------------------ -------- ------------------ --------
  Sex                                                                                                                                                        
  Female                                                                                                      Reference                                       
  Male                                                                                                        ---                .108                         
  Age at diagnosis                                                                                                                                           
  \<60 y                    Reference                                             Reference                   Reference                   Reference           
  60‐80 y                   1.10 (0.79‐1.54)           .574                       0.97 (0.63‐1.49)   .877     1.22 (1.13‐1.32)   \<.001   1.20 (1.08‐1.34)   .001
  \>80 y                    1.99 (1.28‐3.07)           .002                       1.92 (1.09‐3.35)   .023     1.54 (1.39‐1.70)   \<.001   1.59 (1.38‐1.84)   \<.001
  Race                                                                                                                                                       
  Non‐Hispanic White                                                                                                                                          
  Non‐Hispanic Black                                                                                                                                          
  Hispanic                                                                                                                                                    
  Others                                                                                                                                                      
  Marital status                                                                                                                                             
  Married                   Reference                                             Reference                   Reference                   Reference           
  Divorced/separated        ---                        .264                       ---                .916     ---                .240     1.17 (1.02‐1.34)   .030
  Windowed                  ---                        .473                       ---                .006     ---                .596     1.14 (1.02‐1.28)   .025
  Single                    ---                        .913                       ---                .750     ---                .228     1.15 (1.01‐1.31)   .037
  Histological type                                                                                                                                          
  Adenocarcinoma                                                                  Reference                   Reference                   Reference           
  Squamous cell carcinoma                                                         1.80 (1.07‐3.05)   .028     ---                .029     1.30 (1.04‐1.62)   .021
  Others                                                                          0.65 (0.40‐1.05)   .076     ---                .607     0.84 (0.75‐0.94)   .003
  Grade                                                                                                                                                      
  Grade I                   Reference                                                                         Reference                   Reference           
  Grade II                  1.18 (0.64‐2.16)           .598                                                   1.26 (1.04‐1.53)   .018     1.24 (0.97‐1.59)   .090
  Grade III                 1.80 (0.99‐3.27)           .053                                                   1.71 (1.42‐2.07)   \<.001   1.69 (1.33‐2.15)   \<.001
  Grade IV                  1.30 (0.49‐3.48)           .602                                                   1.59 (1.19‐2.14)   .002     1.83 (1.26‐2.66)   .002
  Unknown                   1.05 (0.56‐1.95)           .888                                                   1.51 (1.25‐1.83)   \<.001   1.40 (1.10‐1.79)   .007
  Treatment pattern                                                                                                                                          
  No surgery/No CT          Reference                                             Reference                   Reference                   Reference           
  Surgery                   0.69 (0.48‐1.01)           .058                       0.72 (0.44‐1.16)   .171     0.60 (0.54‐0.66)   \<.001   0.64 (0.56‐0.74)   \<.001
  CT                        0.58 (0.39‐0.87)           .008                       0.51 (0.29‐0.90)   .019     0.43 (0.40‐0.47)   \<.001   0.44 (0.39‐0.49)   \<.001
  Surgery + CT              0.32 (0.21‐0.48)           \<.001                     0.36 (0.22‐0.60)   \<.001   0.29 (0.26‐0.33)   \<.001   0.33 (0.29‐0.39)   \<.001

Abbreviations: AJCC, American Joint Committee on Cancer; CSS, cancer‐specific survival; CT, chemotherapy; Grade I, well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; Grade IV, undifferentiated; OS, overall survival.

Model was adjusted by age, marital status, grade, and treatment pattern.

Model was adjusted by age, marital status, histological type, and treatment pattern.

Model was adjusted by sex, age, marital status, histological type, grade, and treatment pattern.

Model was adjusted by age, marital status, histological type, grade, and treatment pattern.
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![Overall survival and cancer‐specific survival curves of advanced gallbladder cancer patients according to different American Joint Committee on Cancer (AJCC) stage. A and B, Overall survival and cancer‐specific survival of AJCC stage III patients; C and D, Overall survival and cancer‐specific survival of AJCC stage IV patients](CAM4-9-141-g003){#cam42679-fig-0003}

3.4. Identification of prognostic factors of OS and CSS in 1:1 PSM sample {#cam42679-sec-0014}
-------------------------------------------------------------------------

To better balance the patients with AJCC stage III or AJCC stage IV GBC, we performed a 1:1 PSM for variables such as diagnosis age, race, marital status, tumor grade, and treatment pattern to decrease the selection bias and further examine the relationship between treatment patterns and OS and CSS, as assessed with the Cox regression model.

First, we performed univariate and multivariate Cox regression analysis of all patients after PSM, and found that only diagnosis age and treatment pattern were independent risk factors (Table [S1](#cam42679-sup-0003){ref-type="supplementary-material"}). "Surgery + CT" significantly improved the OS (vs "No surgery/No CT"; HR = 0.28, 95% CI 0.21‐0.37, *P* \< .001) and CSS (vs "No surgery/No CT"; HR = 0.30, 95% CI 0.22‐0.43, *P* \< .001) (Figure [S1](#cam42679-sup-0001){ref-type="supplementary-material"}).

Moreover, we performed AJCC stage stratification on patient parameters after PSM on the basis of multivariate analysis. We found that the treatment pattern was also an independent risk factor for AJCC stage IV patients (Table [S2](#cam42679-sup-0003){ref-type="supplementary-material"}), and "Surgery + CT" significantly improved the OS (vs "No surgery/No CT"; HR = 0.23, 95% CI 0.15‐0.35, *P* \< .001) and CSS (vs "No surgery/No CT"; HR = 0.31, 95% CI 0.19‐0.52, *P* \< .001) of AJCC stage IV patients after PSM (Figure [S2](#cam42679-sup-0002){ref-type="supplementary-material"}).

4. DISCUSSION {#cam42679-sec-0015}
=============

Currently, the treatment of patients with advanced GBC remains controversial. Radical surgical resection is the only possible cure treatment for patients with GBC. However, most patients with GBC are at an advanced stage at the time of discovery, thus limiting the opportunity for radical resection; even in the moderate stage, the prognosis of patients undergoing radical resection is highly unsatisfactory. Therefore, clinicians have been exploring the application and combination of adjuvant treatments, including RT, CT, and other treatments, to improve the prognosis of patients with GBC.

Radical surgical resection remains the most important treatment for improving the survival rate of patients with GBC.[13](#cam42679-bib-0013){ref-type="ref"} Surgeons have long been pessimistic about the treatment of advanced GBC. In recent years, owing to the development of GBC radical surgery, the long‐term survival rate has significantly improved. Nakamura et al[14](#cam42679-bib-0014){ref-type="ref"} have reported that in 33 GBC patients with Nevin V stage, 13 patients underwent extended radical resection, and the 1‐year and 3‐year survival rates were 46% and 23%, respectively, whereas the 1‐year survival rate of 20 patients without resection was only 15%. Matsumoto et al[15](#cam42679-bib-0015){ref-type="ref"} reported that the average survival time of 15 patients undergoing extended radical resection was 26 months, whereas that of patients who did not undergo resection was only 10 months.

Patients in stage IV are generally considered unable to undergo surgical resection,[1](#cam42679-bib-0001){ref-type="ref"} but many clinical studies have supported more aggressive surgical treatment of patients with advanced GBC.[16](#cam42679-bib-0016){ref-type="ref"}, [17](#cam42679-bib-0017){ref-type="ref"} Kang\'s[17](#cam42679-bib-0017){ref-type="ref"} study has shown that radical surgery in stage IV GBC patients can prolong survival time. Christina et al[18](#cam42679-bib-0018){ref-type="ref"} have further confirmed this conclusion, suggesting that radical surgery can be performed in stage IV patients as long as the lesion is local and can reach the R0 margin. Studies from Japan also suggest that if the tumor is relatively limited and strictly screened, even if the lesion is large and has invaded adjacent organs, stage IV patients are expected to achieve long‐term survive after radical resection.[19](#cam42679-bib-0019){ref-type="ref"}, [20](#cam42679-bib-0020){ref-type="ref"}, [21](#cam42679-bib-0021){ref-type="ref"}, [22](#cam42679-bib-0022){ref-type="ref"} However, increased surgical complications and mortality have hampered the adoption of these radical surgical approaches as a standard treatment for GBC.[23](#cam42679-bib-0023){ref-type="ref"} Similarly, big data research from Japan does not support radical surgical resection in patients in stage IV, and some studies have indicated that radical surgery does not improve prognosis in patients in stage IV.[24](#cam42679-bib-0024){ref-type="ref"}, [25](#cam42679-bib-0025){ref-type="ref"}

According to the 7th edition of AJCC guidelines, patients with stage T4 are usually considered unresectable and should be treated with palliative care.[26](#cam42679-bib-0026){ref-type="ref"} Groot et al[27](#cam42679-bib-0027){ref-type="ref"} have suggested that patients with stage T4 GBC are unlikely to benefit from surgical resection. However, there is currently no consensus regarding the factors indicating unresectable advanced GBC.[28](#cam42679-bib-0028){ref-type="ref"} Recent reports have shown that radical resection and arteriotomy in advanced GBC, or enlarged right trifoliate resection and hepatopancreatic duodenectomy (HPD) can improve patient prognosis.[29](#cam42679-bib-0029){ref-type="ref"}, [30](#cam42679-bib-0030){ref-type="ref"} Nishio et al[31](#cam42679-bib-0031){ref-type="ref"} have suggested that radical resection also has value for GBC invading the extrahepatic bile duct also. Anil et al[32](#cam42679-bib-0032){ref-type="ref"} have indicated that even duodenal infiltration of GBC does not indicate that surgical removal is impossible. Our study also shows that the surgery improves OS and CSS in patients with AJCC stage III or AJCC stage IV GBC.

Although surgical radical resection of the GBC is currently extensively performed, the rate of radical resection is only 25%‐30%. After radical resection, nearly half of patients still have a risk of recurrence of GBC. Therefore, to decrease the postoperative recurrence of GBC patients and improve the prognosis of patients with advanced disease, some patients are given CT treatment. At present, gemcitabine combined with oxaliplatin (GEMOX) or cisplatin and tegafur combined with oxaliplatin (SOX) are widely used and recognized as effective chemotherapy regimens for GBC patients.[33](#cam42679-bib-0033){ref-type="ref"}, [34](#cam42679-bib-0034){ref-type="ref"}

In this large population‐based study, we used the SEER database to analyze the best treatment options for patients with advanced GBC. Through univariate and multivariate Cox survival regression analysis, in all patients, AJCC stage III patients and AJCC stage IV patients, we found that the "Surgery + CT" treatment significantly increase the OS (vs "No surgery/No CT"; HR = 0.29, 95% CI 0.26‐0.33, *P* \< .001) and CSS (vs "No surgery/No CT"; HR = 0.33, 95% CI 0.29‐0.39, *P* \< .001). The results of 1:1 PSM analysis also showed that the "Surgery + CT" treatment significantly decreased the risk of death in patients with advanced GBC. In addition, the proportion of patients with "Surgery + CT" remained relatively stable over the past 12 years, and "Surgery + CT" may not currently be fully utilized. The combination of surgery and CT may improve the survival rate of patients with advanced GBC.

This study has several limitations. First, it was a retrospective study and thus had clear inherent limitations. Second, the SEER database lacked information about the physical condition and complications of patients, and older patients may be more likely to choose conservative treatment. In addition, the sequence of surgery and CT, as well as the specific regimen of CT was unknown. Nonetheless, the study remains convincing given the large demographics.

5. CONCLUSIONS {#cam42679-sec-0016}
==============

We found that the "Surgery + CT" treatment model provided greater survival benefits for patients with advanced GBC. Because this was a retrospective analysis, further prospective studies are needed to provide verification.
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